Insmed Q2 FY26 net loss narrows to $13.2 million; revenue rises 296% to $425.5 million
INSM•Q2 revenue rises 296% as net loss narrows
Insmed posted Q2 2026 revenue of $425.5 million, up 296% from Q2 2025, driven by BRINSUPRI revenue of $309.2 million.
Net loss narrowed to $13.2 million, or $0.06 per share, from a $321.7 million loss a year earlier.
Expenses increase and product revenue guidance raised
Research and development expense rose to $210 million from $177.2 million, while selling, general and administrative expense climbed to $247.5 million from $154.8 million.
BRINSUPRI revenue grew 49% versus Q1 2026; ARIKAYCE revenue increased 8% versus Q2 2025 to $116.3 million.
The company raised its 2026 BRINSUPRI revenue guidance to $1.25 billion-$1.4 billion and reiterated 2026 ARIKAYCE guidance of $450 million-$470 million.
